European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - imipenem monohydrate, cilastatin sodium, relebactam monohydrate - gram-negative bacterial infections - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4.4 and 5.1).- treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults.- treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4, and 5.1).consideration should be given to official guidance on the appropriate use of antibacterial agents.

United States - English - NLM (National Library of Medicine)

hospira, inc. - imipenem (unii: 71otz9ze0a) (imipenem anhydrous - unii:q20im7he75), cilastatin sodium (unii: 5428wxz74m) (cilastatin - unii:141a6amn38) - imipenem anhydrous 250 mg in 100 ml - imipenem and cilastatin for injection (i.v.) for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of staphylococcus aureus (penicillinase-producing isolates), acinetobacter species, enterobacter species, escherichia coli , haemophilus influenzae , haemophilus parainfluenzae , klebsiella species, serratia marcescens. imipenem and cilastatin for injection (i.v.) is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of enterococcus faecalis , staphylococcus aureus (penicillinase-producing isolates), enterobacter species, escherichia coli , klebsiella species, morganella morganii , proteus vulgaris , providencia rettgeri , pseudomonas aeruginosa. imipenem and cilastatin for injection (i.v.) is indicated for the treatment of intra-abdominal infections caused by susceptible strains of enterococcus faecalis , staphylococcus aureus (penicillinase-producing isolates), staphylococ

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - imipenem (unii: 71otz9ze0a) (imipenem anhydrous - unii:q20im7he75), cilastatin sodium (unii: 5428wxz74m) (cilastatin - unii:141a6amn38) - imipenem anhydrous 250 mg in 20 ml - imipenem and cilastatin for injection, usp (i.v.) for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of staphylococcus aureus (penicillinase-producing isolates), acinetobacter species, enterobacter species, escherichia coli , haemophilus influenzae , haemophilus parainfluenzae , klebsiella species, serratia marcescens . imipenem and cilastatin for injection, usp (i.v.) is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of enterococcus faecalis , staphylococcus aureus (penicillinase-producing isolates), enterobacter species, escherichia coli , klebsiella species, morganella morganii , proteus vulgaris , providencia rettgeri ,

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - imipenem; cilastatin - powder for solution for infusion - 250 mg/250 milligram(s) - imipenem and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - imipenem; cilastatin - powder for solution for infusion - 500 mg/500 milligram(s) - imipenem and enzyme inhibitor

Malta - English - Medicines Authority

apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - imipenem, cilastatin - powder for solution for infusion - imipenem 500 mg cilastatin 500 mg - antibacterials for systemic use

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - imipenem anhydrous (unii: q20im7he75) (imipenem anhydrous - unii:q20im7he75), cilastatin (unii: 141a6amn38) (cilastatin - unii:141a6amn38), relebactam anhydrous (unii: 1oqf7tt3pf) (relebactam anhydrous - unii:1oqf7tt3pf) - recarbrio™ is indicated for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: acinetobacter calcoaceticus-baumannii complex, enterobacter cloacae , escherichia coli , haemophilus influenzae , klebsiella aerogenes, klebsiella oxytoca, klebsiella pneumoniae, pseudomonas aeruginosa, and serratia marcescens. recarbrio is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cuti), including pyelonephritis, caused by the following susceptible gram-negative microorganisms: enterobacter cloacae , escherichia coli , klebsiella aerogenes, klebsiella pneumoniae, and pseudomonas aeruginosa . approval of this indication is based on limited clinical safety and efficacy data for recarbrio [see clinical studies (14.2)] . recarbrio is indicated in patients

Ireland - English - HPRA (Health Products Regulatory Authority)

hikma farmacêutica (portugal) s.a. - imipenem; cilastatin - powder for solution for infusion - 500 mg/500 milligram(s) - carbapenems; imipenem and enzyme inhibitor

Canada - English - Health Canada

sandoz canada incorporated - imipenem; cilastatin (cilastatin sodium) - powder for solution - 250mg; 250mg - imipenem 250mg; cilastatin (cilastatin sodium) 250mg - carbapenems

Canada - English - Health Canada

sandoz canada incorporated - imipenem; cilastatin (cilastatin sodium) - powder for solution - 500mg; 500mg - imipenem 500mg; cilastatin (cilastatin sodium) 500mg - carbapenems